Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?

Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study Publisher Pubmed

Willasch AM¹ ; Peters C² ; Sedlacek P³ ; Dalle JH⁴ ; Kitraroussou V⁵ ; Yesilipek A⁶ ; Wachowiak J⁷ ; Lankester A⁸ ; Prete A⁹ ; Hamidieh AA¹⁰ ; Ifversen M¹¹ ; Buechner J¹² ; Krivan G¹³ ; Hamladji RM¹⁴ Show All Authors

Willasch AM¹
Peters C²
Sedlacek P³
Dalle JH⁴
Kitraroussou V⁵
Yesilipek A⁶
Wachowiak J⁷
Lankester A⁸
Prete A⁹
Hamidieh AA¹⁰
Ifversen M¹¹
Buechner J¹²
Krivan G¹³
Hamladji RM¹⁴
Diazdeheredia C¹⁵
Skorobogatova E¹⁶
Michel G¹⁷
Locatelli F^{18, 19}
Bertaina A^{18, 19, 20}
Veys P²¹
Dupont S²²
Or R²³
Gungor T²⁴
Aleinikova O²⁵
Sufliarska S²⁶
Sundin M²⁷
Rascon J²⁸
Kaare A²⁹
Nemet D³⁰
Fagioli F³¹
Klingebiel TE¹
Styczynski J³²
Bierings M³³
Nagy K³⁴
Abecasis M³⁵
Afanasyev B³⁶
Ansari M³⁷
Vettenranta K³⁸
Alseraihy A³⁹
Chybicka A⁴⁰
Robinson S⁴¹
Bertrand Y⁴²
Kupesiz A⁴³
Ghavamzadeh A⁴⁴
Campos A⁴⁵
Pichler H²
Dalissier A⁴⁶
Labopin M⁴⁷
Corbacioglu S⁴⁸
Balduzzi A⁴⁹
Galimard JE⁴⁶
Bader P¹

Source: Bone Marrow Transplantation Published:2020

Abstract

Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.

Related Docs

View other Related Docs

1. Total Body Irradiation-Free Haploidentical Peripheral Blood Stem Cell Transplantation Compared to Related and Unrelated Donor Transplantation in Pediatrics With Acute Lymphoblastic Leukemia, Pediatric Blood and Cancer (2023)

2. A Single-Center Experience With Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: A Modest Pitch for Non-Total Body Irradiation Conditioning Regimens, Experimental and Clinical Transplantation (2019)

3. A Comprehensive Comparison Between Tbi Vs Non-Tbi-Based Conditioning Regimen in Pediatric Patients With Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis, Leukemia Research (2023)

Experts (# of related papers)

View all Related Experts

Amir Kasaeian (7)

Amir Ali Hamidieh (7)

Style	Citing Format
MLA	Willasch AM, et al.. "Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study." Bone Marrow Transplantation, vol. 55, no. 8, 2020, pp. 1540-1551.
APA	Willasch AM, Peters C, Sedlacek P, Dalle JH, Kitraroussou V, Yesilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AA, Ifversen M, Buechner J, Krivan G, Hamladji RM, Diazdeheredia C, Skorobogatova E, Michel G, Locatelli F, Bertaina A, ... Bader P (2020). Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study. Bone Marrow Transplantation, 55(8), 1540-1551.
Chicago	Willasch AM, Peters C, Sedlacek P, Dalle JH, Kitraroussou V, Yesilipek A, Wachowiak J, et al.. "Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study." Bone Marrow Transplantation 55, no. 8 (2020): 1540-1551.
Harvard	Willasch AM et al. (2020) 'Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study', Bone Marrow Transplantation, 55(8), pp. 1540-1551.
Vancouver	Willasch AM, Peters C, Sedlacek P, Dalle JH, Kitraroussou V, Yesilipek A, et al.. Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study. Bone Marrow Transplantation. 2020;55(8):1540-1551.
BibTex	@article{ author = {Willasch AM and Peters C and Sedlacek P and Dalle JH and Kitraroussou V and Yesilipek A and Wachowiak J and Lankester A and Prete A and Hamidieh AA and Ifversen M and Buechner J and Krivan G and Hamladji RM and Diazdeheredia C and Skorobogatova E and Michel G and Locatelli F and Bertaina A and Veys P and Dupont S and Or R and Gungor T and Aleinikova O and Sufliarska S and Sundin M and Rascon J and Kaare A and Nemet D and Fagioli F and Klingebiel TE and Styczynski J and Bierings M and Nagy K and Abecasis M and Afanasyev B and Ansari M and Vettenranta K and Alseraihy A and Chybicka A and Robinson S and Bertrand Y and Kupesiz A and Ghavamzadeh A and Campos A and Pichler H and Dalissier A and Labopin M and Corbacioglu S and Balduzzi A and Galimard JE and Bader P}, title = {Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study}, journal = {Bone Marrow Transplantation}, volume = {55}, number = {8}, pages = {1540-1551}, year = {2020} }
RIS	TY - JOUR AU - Willasch AM AU - Peters C AU - Sedlacek P AU - Dalle JH AU - Kitraroussou V AU - Yesilipek A AU - Wachowiak J AU - Lankester A AU - Prete A AU - Hamidieh AA AU - Ifversen M AU - Buechner J AU - Krivan G AU - Hamladji RM AU - Diazdeheredia C AU - Skorobogatova E AU - Michel G AU - Locatelli F AU - Bertaina A AU - Veys P AU - Dupont S AU - Or R AU - Gungor T AU - Aleinikova O AU - Sufliarska S AU - Sundin M AU - Rascon J AU - Kaare A AU - Nemet D AU - Fagioli F AU - Klingebiel TE AU - Styczynski J AU - Bierings M AU - Nagy K AU - Abecasis M AU - Afanasyev B AU - Ansari M AU - Vettenranta K AU - Alseraihy A AU - Chybicka A AU - Robinson S AU - Bertrand Y AU - Kupesiz A AU - Ghavamzadeh A AU - Campos A AU - Pichler H AU - Dalissier A AU - Labopin M AU - Corbacioglu S AU - Balduzzi A AU - Galimard JE AU - Bader P TI - Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study JO - Bone Marrow Transplantation VL - 55 IS - 8 SP - 1540 EP - 1551 PY - 2020 ER -

Style

Citing Format

MLA

Willasch AM, et al.. "Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study." Bone Marrow Transplantation, vol. 55, no. 8, 2020, pp. 1540-1551.

APA

Willasch AM, Peters C, Sedlacek P, Dalle JH, Kitraroussou V, Yesilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AA, Ifversen M, Buechner J, Krivan G, Hamladji RM, Diazdeheredia C, Skorobogatova E, Michel G, Locatelli F, Bertaina A, ... Bader P (2020). Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study. Bone Marrow Transplantation, 55(8), 1540-1551.

Chicago

Willasch AM, Peters C, Sedlacek P, Dalle JH, Kitraroussou V, Yesilipek A, Wachowiak J, et al.. "Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study." Bone Marrow Transplantation 55, no. 8 (2020): 1540-1551.

Harvard

Willasch AM et al. (2020) 'Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study', Bone Marrow Transplantation, 55(8), pp. 1540-1551.

Vancouver

Willasch AM, Peters C, Sedlacek P, Dalle JH, Kitraroussou V, Yesilipek A, et al.. Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study. Bone Marrow Transplantation. 2020;55(8):1540-1551.

BibTex

@article{ author = {Willasch AM and Peters C and Sedlacek P and Dalle JH and Kitraroussou V and Yesilipek A and Wachowiak J and Lankester A and Prete A and Hamidieh AA and Ifversen M and Buechner J and Krivan G and Hamladji RM and Diazdeheredia C and Skorobogatova E and Michel G and Locatelli F and Bertaina A and Veys P and Dupont S and Or R and Gungor T and Aleinikova O and Sufliarska S and Sundin M and Rascon J and Kaare A and Nemet D and Fagioli F and Klingebiel TE and Styczynski J and Bierings M and Nagy K and Abecasis M and Afanasyev B and Ansari M and Vettenranta K and Alseraihy A and Chybicka A and Robinson S and Bertrand Y and Kupesiz A and Ghavamzadeh A and Campos A and Pichler H and Dalissier A and Labopin M and Corbacioglu S and Balduzzi A and Galimard JE and Bader P}, title = {Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study}, journal = {Bone Marrow Transplantation}, volume = {55}, number = {8}, pages = {1540-1551}, year = {2020} }

RIS

TY - JOUR
AU - Willasch AM
AU - Peters C
AU - Sedlacek P
AU - Dalle JH
AU - Kitraroussou V
AU - Yesilipek A
AU - Wachowiak J
AU - Lankester A
AU - Prete A
AU - Hamidieh AA
AU - Ifversen M
AU - Buechner J
AU - Krivan G
AU - Hamladji RM
AU - Diazdeheredia C
AU - Skorobogatova E
AU - Michel G
AU - Locatelli F
AU - Bertaina A
AU - Veys P
AU - Dupont S
AU - Or R
AU - Gungor T
AU - Aleinikova O
AU - Sufliarska S
AU - Sundin M
AU - Rascon J
AU - Kaare A
AU - Nemet D
AU - Fagioli F
AU - Klingebiel TE
AU - Styczynski J
AU - Bierings M
AU - Nagy K
AU - Abecasis M
AU - Afanasyev B
AU - Ansari M
AU - Vettenranta K
AU - Alseraihy A
AU - Chybicka A
AU - Robinson S
AU - Bertrand Y
AU - Kupesiz A
AU - Ghavamzadeh A
AU - Campos A
AU - Pichler H
AU - Dalissier A
AU - Labopin M
AU - Corbacioglu S
AU - Balduzzi A
AU - Galimard JE
AU - Bader P
TI - Myeloablative Conditioning for Allo-Hsct in Pediatric All: Ftbi or Chemotherapy?—A Multicenter Ebmt-Pdwp Study
JO - Bone Marrow Transplantation
VL - 55
IS - 8
SP - 1540
EP - 1551
PY - 2020
ER -

Science Communicator Platform

Authors

Abstract